Hannover Medical School, Divisions of Paediatric Gastroenterology and Hepatology, Department for Paediatric Kidney, Liver, and Metabolic Diseases, Hannover, Germany.
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Pediatrics. 2022 Oct 1;150(4). doi: 10.1542/peds.2022-057424.
The European Liver Transplant Registry has been collecting data on virtually all pediatric liver transplant (PLT) procedures in Europe since 1968. We analyzed patient outcome over time and identified parameters associated with long-term patient outcome.
Participating centers and European organ-sharing organizations provided retrospective data to the European Liver Transplant Registry. To identify trends, data were grouped into consecutive time spans: era A: before 2000, era B: 2000 to 2009, and the current era, era C: since 2010.
From June 1968 until December 2017, 16 641 PLT were performed on 14 515 children by 133 centers. The children <7 years of age represented 58% in era A, and 66% in the current era (P <.01). The main indications for PLT were congenital biliary diseases (44%) and metabolic diseases (18%). Patient survival at 5 years is currently 86% overall and 97% in children who survive the first year after PLT. The survival rate has improved from 74% in era A to 83% in era B and 85% in era C (P <.0001). Low-volume centers (<5 PLT/year) represented 75% of centers but performed only 19% of PLT and were associated with a decreased survival rate. In the current era, however, survival rates has become irrespective of volume. Infection is the leading cause of death (4.1%), followed by primary nonfunction of the graft (1.4%).
PLT has become a highly successful medical treatment that should be considered for all children with end-stage liver disease. The main challenge for further improving the prognosis remains the early postoperative period.
自 1968 年以来,欧洲肝移植登记处(ELTR)一直在收集欧洲几乎所有儿科肝移植(PLT)手术的数据。我们分析了患者随时间的转归,并确定了与长期患者转归相关的参数。
参与中心和欧洲器官共享组织向欧洲肝移植登记处提供回顾性数据。为了识别趋势,将数据分为连续时间段:A 时代:2000 年之前;B 时代:2000 年至 2009 年;当前时代,C 时代:2010 年以来。
从 1968 年 6 月至 2017 年 12 月,133 个中心为 14515 名儿童进行了 16641 例 PLT。A 时代<7 岁的儿童占 58%,当前时代占 66%(P<.01)。PLT 的主要适应证为先天性肝胆疾病(44%)和代谢性疾病(18%)。目前,患者 5 年生存率总体为 86%,PLT 后存活 1 年的患儿为 97%。生存率从 A 时代的 74%提高到 B 时代的 83%和 C 时代的 85%(P<.0001)。低容量中心(<5 例/年)占中心的 75%,但仅进行了 19%的 PLT,且与生存率降低相关。然而,在当前时代,生存率与容量无关。感染是导致死亡的主要原因(4.1%),其次是移植物原发性无功能(1.4%)。
PLT 已成为一种非常成功的治疗方法,应考虑用于所有终末期肝病患儿。进一步改善预后的主要挑战仍然是术后早期。